GlassScriptPhysician profile
Abdul Rahman Halabi
NPI 1992767578
$14,943.82
in general payments reported to CMS, 2019-2025
36 companies · $1,432 in 2025
The $1,432 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $506 · 2021: $2,305 · 2022: $2,960 · 2023: $3,938 · 2024: $2,345 · 2025: $1,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,918 · Travel and Lodging: $1,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,917.56 |
| Travel and Lodging | $1,796.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endologix LLC | $4,916.51 | 2019-2025 | Alto Abdominal Stent Graft System, Endocross Device, Torus Stent Graft System |
| Inari Medical, INC. | $2,305.14 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boston Scientific Corporation | $2,099.03 | 2021-2024 | |
| Edwards Lifesciences Corporation | $1,169.58 | 2019-2024 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $951.11 | 2020-2025 | Perclose Prostyle, Optis, Coroflow |
| Medtronic, INC. | $899.45 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Janssen Pharmaceuticals, INC | $318.48 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $310.92 | 2020-2025 | |
| Shockwave Medical, INC | $230.21 | 2025 | |
| Amgen INC. | $199.34 | 2021-2025 | Tavneos, Repatha |
| Lexicon Pharmaceuticals, INC. | $168.61 | 2024 | Inpefa |
| Merck Sharp & Dohme LLC | $162.90 | 2022-2025 | Verquvo |
| Medtronic Vascular, INC. | $159.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $147.72 | 2019-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $142.53 | 2021-2023 | Arcalyst |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.87 | 2023-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $124.98 | 2024 | Assure Wcd |
| Pfizer INC. | $78.76 | 2022-2025 | |
| Baxter Healthcare | $73.38 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $60.05 | 2022-2025 | Camzyos |
| W. L. Gore & Associates, INC. | $35.75 | 2023 | Gore Cardioform Septal Occluder |
| Actelion Pharmaceuticals US, INC. | $31.15 | 2024 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $29.90 | 2021 | |
| Cleerly, INC. | $29.81 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Novo Nordisk INC | $24.90 | 2024 | Wegovy |
| Cardiva Medical, INC. | $24.49 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Regeneron Healthcare Solutions, INC. | $20.61 | 2021 | |
| Cvrx, INC. | $20.03 | 2024 | Barostim Neo System |
| Tactile Systems Technology INC | $19.09 | 2025 | Nimbl, Flexitouch Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.97 | 2025 | Jardiance |
| Teleflex LLC | $16.95 | 2025 | Pk Papyrus |
| Abiomed | $14.56 | 2025 | |
| Cardinal Health 200 LLC | $11.96 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$50,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Halabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.